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Background: Human papillomavirus (HPV) is the most significant cause of cervical cancer.In view of the number
of drawbacks associated with endocervicalsampling, the gold standardfor HPV detection,thisstudyexamined the
utilityandspecificityofvaginalsamplingasanalternativeforendocervicalsamplingfortheroutinedetectionofHPV.
Case study: The study comprised 51 women who tested positive and 54 women who tested negative for
endocervical HPV by polymerase chain reaction (PCR), confirmed by histopathology. At the time of specimen
collection, both (speculum-assisted) endocervical and vaginal (no speculum) scrapings were isolated from HPV-
positiveandnegativewomen,andHPVDNAwasassessedbyPCRusingtheMY09/MY11primersystem;HPVtype
was identified by hybridization of PCR products with type-specific biotinylated DNA probes. Each participant
served as her own control. HPV was detected in vaginal and cervical scrapes from all HPV-positive but not
HPV-negativewomen.In HPV-positivewomen thesame HPVtypewasfoundinvaginalandendocervicalscrapings
(positive predictive value = 1.0).
Conclusion: Correlation between vaginal and endocervical sampling methods was excellent in detecting the
presence of HPV DNA and for identifying distinct HPV genotypes. Utilization of vaginal testing for routine HPV
detection, and for the long-term follow-up of persistent HPV infection, is therefore recommended.
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INTRODUCTION
Human papillomavirus (HPV) is the most signifi-
cantsexuallytransmitted causative agentofcervical
intraepithelial neoplasia (CIN)1,2, of which more
than 100 types have been characterized3. Tradi-
tional screening for HPV infection relied on the
Pap smear. Although the Pap smear has been
widely adopted in the initial screening for CIN,
the high number of false negatives and positives
associated with it4,5, coupled with the need for
highly sensitive methods for detecting HPV
infection in high-risk women and women highly
suspected of infection, has necessitated a search for
alternative methods for HPV screening to assess
cervical neoplasia. Identification of HPV DNA by
molecular biology tools, in particular polymerase
chainreaction(PCR),hasbeenreportedbyseveral
investigators to be more sensitive than cytology in
the identification, and also in the monitoring of
the progression, of CIN disease5,6.
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Gynecologic case report 119Several methods have been used in detecting
HPV infection, including PCR4,5,7, which relies
on isolating endocervicalepithelial cells by a gyne-
cologist using a speculum and subsequent DNA
analysis. However, this technique is associated
withdrawbackswith regardtopatientcompliance,
its invasive nature, and the poor yield of tissue for
repetitive sampling8, prompting investigation into
alternative methods, includingvaginal testing, that
yield sufficient cells without inconveniencing the
patient8,9. Varied concordance rates have been
obtained between speculum-assisted endocervical
sampling and other collection methods1,8,9, high-
lighting the need for refinements in specimen
collection and further manipulation. Here we
extend earlier findings by demonstrating the use-
fulnessandsensitivity ofvaginaltestingindetecting
HPVgenotypes.ThepresenceofHPV andb-actin
DNA sequences in endocervical and vaginal
scrapes was assessed in HPV-positive and HPV-
negative women; complete concordance between




followed because of confirmed endocervical HPV
infection, the remaining 54 women being free of
HPV as assessed by immunohistochemistry and
confirmed by PCR. For the purpose of this study
both endocervical and vaginal specimens were
collected at the same time to minimize variations
in viral load, and hence sensitivity, between visits.
All participants were asked to complete a standard
questionnaire that details age, marital status, smok-
ing, pregnancies, number of sexual partners, con-
current infections and results of Pap smear (and
date taken). After the purpose and implications of
the findings were explained to all participants, and
after all institutional ethics requirements were met,




Endocervical scrapes were collected by speculum-
assisted spatula of Ayre after removing the mucus,
and were placed in balanced saline solution.
Vaginal scrapes were collected by introduction of
the sterile spatula of Ayre after separating the labia
minora (to visualize the introitus), followed by
intra-vaginal 180° rotation to collect scrapings,
which were immediately placed in balanced saline
solution. Total genomic DNA was extracted by
the phenol–chloroform method, as is standard in
our laboratory.
HPV DNA amplification
DNA samples were amplified with the L1 con-
sensus HPV primers MY09/MY117. The primer
sequences for MY09 are 5’-CGT CC(A,C)
A(A,G)(A,G) GGA(A,T)ACTGA TC-3’, and for
MY11, 5’-GC(A,C) CAG GG(A,T) CAT
AA(C,T) AAT GG-3’. Amplification of the
‘house-keeping’ gene, b-actin, was performed in
parallel on every sample in order to control for
DNA integrity and to rule out the presence of
inhibitors of amplification. The primer sequences
for b-actin were: forward, 5’-GTG GGG CGC
CCC AGG CAC CA-3’, and reverse, 5’-CTC
CTT AATGTC ACG CAC GAT TTC-3’. PCR
conditions comprised an initial denaturation for
2.5 min at 96°C, 41 cycles of denaturation for 30 s
at 92°C, annealing for 30 s at 56°C, and extension
for 45 s at 72°C. PCR products were electro-
phoresed onethidiumbromide-stained agarose gel
(2%), and visualized under UV-transillumination.
HPV genotypeswere determinedbyhybridization
with genotype-specific biotinylated DNA probes,
and visualized by DNA enzyme immunoassay




A total of 105 women participated in the study, of
whom 51 were HPV-positive and 54 were HPV-
negative, as shown by the ‘gold standard’, endo-
cervical HPV detection. While there was no
statistically significant difference between HPV-
positiveandHPV-negative womenwithrespectto
age (32.9 ± 8.3 and 32.5 ± 6.9 years, respectively,
p = 0.93), those who had had at least one preg-
nancy (36/51 and 33/54, respectively, p = 0.404),
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p = 0.078), or to those with more than one
male partner (35/51 and 22/54, respectively,
p = 0.073), a higher prevalence of abnormal Pap
smear was seen in HPV-positive compared with
HPV-negative women (41/51 and 6/54, respec-
tively, p < 0.001) (Table 1).
Detection of HPV DNA in cervical and
vaginal scrapings
All endocervical and vaginal samples obtained
from study participants were initially tested for the
presence of b-actin sequences. All were positive
for b-actin, and hence were subjected to PCR-
based amplification of HPV consensus sequences.
Vaginal testing detected HPV DNA in all speci-
mens of the 51 HPV-positive cervical scrapes and
none in the 54 HPV-negative cervical scrapes
(sensitivity, 1.0; specificity, 1.0) (Table 2). Insofar
as all specimens screened were positive for b-actin,
this ruled out the possibility of loss of DNA integ-
rity in samples, and/or nonspecific inhibition of
amplification,demonstratingthatallHPV-positive
andallHPV-negativevaginalspecimensweretruly
positive and negative, respectively, when deter-
mined by cervical scrapes (positive and negative
predictive values = 1.0). Furthermore HPV
type(s) detected in vaginal scrapes was/were iden-
tical to that/those found in cervical scrapes (data
not shown).
DISCUSSION
In comparing vaginal with endocervical scrapes as
the specimen of choice, excellent correlation was
obtained in detecting HPV DNA. In addition,
HPV genotype analysis revealed that both
sampling methods were concordant for 100% of
sample pairs. The sampling device used in this
study,thespatulaofAyre,gave bothconsistentand
reproducible results, especially in women who
were retested (data notshown),in agreement with
reportsdocumentingits superiorityas themeansof
collection rather than self-collected devices
including cotton swabs, brushes, and lavages4,8–10.
The use of the latter were associated with lower
rates of HPV detection.
Vaginal testing afforded a significant improve-
ment in sensitivity and specificity over previous
reports, which showed a correlation of 80–90%
between vaginal and cervical sampling methods8,9.
In the quoted studies failure to produce the 100%
correlation between cervical and vaginal specimen
was most probably the result of sampling
problems4,9,10.Inthisstudy weoptedto use vaginal
scrapes (vs tampons or lavages), which produced
sufficient quantities of cells for analysis8,9. Also, we
routinely tested for the expression of the house-
keeping gene, b-actin, as control for the presence
of genomic DNA. In the present study all samples
assayed were positive for b-actin, thereby ruling
outthepossibility that absence of HPV amplifiable
products was not due to specimen degradation or
to the presence of inhibitors of amplification,
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Variable Total HPV +ve HPV ve p value
n
Age ± SD (years)
Range
Smokers (n (%))
Women who had had at least one pregnancy (n (%))
Women who had had multiple partners (n (%))



























*Student’s t test (two-tailed); **Pearson’s c
2 test; HPV, human papillomavirus
Table 1 Profile of study group
Cervical scrapings







Table 2 HPV DNA in vaginal and cervical scrapes of
HPV-positive (n=51) and HPV-negative (n=54) women;
sensitivity and specificity, as well as positive and negative
predictive values, were 1.0further confirming the consistency and efficacy of
this sampling technique4,8.
HPV DNA was amplified by PCR using the
MY09/MY11 primer pair, described as the primer
pair of choice in detecting HPV DNA7. All cervi-
cal and vaginal scrapes were collected at the same
time to rule outthe possibility of variations in viral
load,and hencesensitivity, betweenthecervix and
vagina6,8. A limitation of our study that could not
be avoided was that vaginal sampling required a
gynecologist/technologist for specimen collec-
tion1,8. Nevertheless, it was less invasive as com-
pared to endocervical sampling, since it did not
require insertion of a speculum for sample collec-
tion. Furthermore it was well tolerated, and none
of the participants experienced any discomfort
duringspecimen collection.Thisdemonstrates the
usefulness and sensitivity of vaginal sampling as an
equally sensitive but less invasive procedure for
detecting the presence of HPV genotypes.
CONCLUSIONS
Vaginal testing is an easy yet highly valid method
for detecting HPV DNA. Correlation between
vaginal and cervical sampling methods was excel-
lent for the presence of HPV DNA and for identi-
fying distinct HPV genotypes. It is recommended
that vaginal sampling should be used in initial
HPV screening, especially in high-risk/suspicious
women with cytomorphologically normal smears,
and/or where cervical testing may not be feasible,
as in virgin girls (insistence on hymen integrity
owing to social/cultural considerations) who may
have contracted HPV through routes other than
intra-vaginal intercourse (deep petting, anal inter-
course, etc.). Furthermore, vaginal screening may
be of use in the long-term follow-up of HPV-
infected women for viral persistence, and hence
monitoring CIN disease status4.
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